DelveInsight’s, “Knee osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Knee osteoarthritis pipeline landscape. It covers the Knee osteoarthritis pipeline drug profiles, including Knee osteoarthritis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Knee osteoarthritis Pipeline Report
Discover the recent advances in knee osteoarthritis treatment drugs @ Knee Osteoarthritis Pipeline Outlook Report
Recent Developmental Activities in the Knee Osteoarthritis Treatment Landscape
Knee Osteoarthritis Overview
Knee osteoarthritis is defined by degeneration of the knee’s articular cartilage—the flexible, slippery material that normally protects bones from joint friction and impact. The condition also involves changes to the bone underneath the cartilage and can affect nearby soft tissues. The defining feature of osteoarthritis is the breakdown and loss of articular cartilage. In the knee, articular cartilage covers the top of the tibia (shinbone), the bottom of the femur (thigh bone) and the back of the patella (kneecap). Articular cartilage protects the surfaces of these bones where they meet at the joint.
Find out more about knee osteoarthritis Pipeline Therapies and knee osteoarthritis Ongoing Clinical Trials Analysis @ Knee Osteoarthritis Treatment Landscape
Knee osteoarthritis Emerging Drugs
JTA-004: Bone Therapeutics
JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain.
MM-II: Moebius Medical
Moebius’s lead product, MM-II, is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary multilamellar liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee pain in osteoarthritic patients. The drug is currently in phase II stage of development.
Knee osteoarthritis Therapeutic Assessment
There are approx. 40+ key companies are developing therapies for Knee osteoarthritis. The companies which have their Knee osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Bone Therapeutics.
Learn more about the emerging knee osteoarthritis pipeline therapies @ Knee Osteoarthritis Ongoing Clinical Trials Analysis
Scope of the Knee Osteoarthritis Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Dive deep into rich insights for new drugs for knee osteoarthritis Medication, visit @ Knee Osteoarthritis Key Players and Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/